Healthy
Conditions
Keywords
Ice Hockey, Cognitive Function, Cognition Brain Supplement, Contact Sport Athletes
Brief summary
This research is being done to investigate the dietary supplement, Synaquell (TM), for effects on brain function in youth contact sport athletes.
Detailed description
This randomized clinical trial will compare a brain health supplement (Synaquell) with placebo in both male and female ice hockey players over the course of an entire season. The repeated measure design will compare pre- and post-season objective brain health parameters, including quantitated EEG (Neurocatch), blood & saliva biomarkers, impact monitoring mouthguard, and a rapid number naming test (King Devick).
Interventions
DIETARY_SUPPLEMENTSynaquell(TM)
7.9 grams (1 scoop) of Synaquell powder mixed with 12 ounces of water two times per day for the duration of the sport season. The daily amount taken by each participant is (15.8 grams).
DIETARY_SUPPLEMENTPlacebo
7.9 grams (1 scoop) of placebo powder mixed with 12 ounces of water two times per day for the duration of the sport season. The daily amount taken by each participant is (15.8 grams). The placebo looks, smells, and tastes like Synaquell but does not contain active ingredient.
Sponsors
Mayo Clinic
Sanford Health
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
DOUBLE (Subject, Investigator)
Masking description
The study staff responsible for distributing SynaquellTM will not be blinded to the intervention, but all subjects and other study staff will be blinded.
Eligibility
Sex/Gender
ALL
Age
13 Years to 19 Years
Healthy volunteers
Yes
Inclusion criteria
* Fluent English Speakers * Medically cleared to play contact sport
Exclusion criteria
* An allergy to the ingredients of Synaquell™ or the placebo (ingredients listed on page * Clinically documented hearing issues, * In-ear hearing aid or cochlear implant * Implanted pacemaker or defibrillator * Metal or plastic implants in skull * Lack of verbal fluency in the English language * History of seizures * Allergy to rubbing alcohol or EEG gel * Pregnancy
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in N100 Amplitude | Baseline, Postseason (approximately 6 months). | Obtained by EEG recording of N100 potential amplitude. This measures is subsequently linearly transformed to a standardized score on a 0-100 scale, with larger peak amplitudes and shorter peak latencies resulting in higher scores. Changes in brain vital sign scores are depicted within a radar plot format, with the transformation process preserving the essential ERP results but enabling practical, simplified interpretation. |
| Change in N100 Latency | Baseline, Postseason (approximately 6 months). | Obtained by EEG recording of N100 potential latency. Increased latencies are indicative of slower responses. Obtained by EEG recording of N100 potential amplitude. This measures is subsequently linearly transformed to a standardized score on a 0-100 scale, with larger peak amplitudes and shorter peak latencies resulting in higher scores. Changes in brain vital sign scores are depicted within a radar plot format, with the transformation process preserving the essential ERP results but enabling practical, simplified interpretation. |
| Change in P300 Amplitude | Baseline, Postseason (approximately 6 months). | Obtained by EEG recording of P300 potential amplitude. Increased amplitudes are indicative of larger signals. This measures is subsequently linearly transformed to a standardized score on a 0-100 scale, with larger peak amplitudes and shorter peak latencies resulting in higher scores. Changes in brain vital sign scores are depicted within a radar plot format, with the transformation process preserving the essential ERP results but enabling practical, simplified interpretation. |
| Change in P300 Latency | Baseline, Postseason (approximately 6 months). | Obtained by EEG recording of P300 potential latency. Increased latencies are indicative of slower responses. This measures is subsequently linearly transformed to a standardized score on a 0-100 scale, with larger peak amplitudes and shorter peak latencies resulting in higher scores. Changes in brain vital sign scores are depicted within a radar plot format, with the transformation process preserving the essential ERP results but enabling practical, simplified interpretation. |
| Change in N400 Amplitude | Baseline, Postseason (approximately 6 months). | Obtained by EEG recording of N400 potential amplitude. Increased amplitudes are indicative of larger signals.This measures is subsequently linearly transformed to a standardized score on a 0-100 scale, with larger peak amplitudes and shorter peak latencies resulting in higher scores. Changes in brain vital sign scores are depicted within a radar plot format, with the transformation process preserving the essential ERP results but enabling practical, simplified interpretation. |
| Change in N400 Latency | Baseline, Postseason (approximately 6 months). | Obtained by EEG recording of N400 potential latency. Increased latencies are indicative of slower responses.This measures is subsequently linearly transformed to a standardized score on a 0-100 scale, with larger peak amplitudes and shorter peak latencies resulting in higher scores. Changes in brain vital sign scores are depicted within a radar plot format, with the transformation process preserving the essential ERP results but enabling practical, simplified interpretation. |
| Change in blood biomarker: NfL | Baseline, postseason (approximately 6 months). | Blood will be at a biomarker level. We will investigate the biomarker neurofilament light (NfL). BDNF. The biomarker will be measured in Nanograms per Milliliter (ng/ml). |
| Change in blood biomarker SNCB. | Baseline, postseason (approximately 6 months). | Blood will be at a biomarker level and B-Synuclein will be investigated. The biomarker will be measured in Nanograms per Milliliter (ng/ml). |
| Change in blood biomarker vWF. | Baseline, postseason (approximately 6 months). | Blood will be at a biomarker level and Von Willebrand Factor (vWF) will be investigated. The biomarker will be measured in Nanograms per Milliliter (ng/ml). |
| Change in blood biomarker SNCA. | Baseline, postseason (approximately 6 months). | Blood will be at a biomarker level and A-Synuclein (SNCA) will be investigated. The biomarker will be measured in Nanograms per Milliliter (ng/ml). |
| Change in blood biomarker BDNF. | Baseline, postseason (approximately 6 months). | Blood will be at a biomarker level and Brain Derived Neurotrophic Factor (BDNF) will be investigated. The biomarker will be measured in Nanograms per Milliliter (ng/ml). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in King-Devick Test (KDT) scored | Baseline, postseason (approximately 6 months). | A rapid number-naming test that requires individuals to read 3 numbered patters aloud as fast as possible, the resulting time if the KDT score. The post-season score is compared to the pre-season baseline. An increase in the number of seconds required to read the 3 number patterns is considered to be significant. |
| Impact Monitor Mouthguard Acceleration | Beginning of practice to last game (approximately 6 months). | The Impact monitor mouthguard measures head acceleration. |
| Impact Monitor Mouthguard Rotation | Beginning of practice to last game (approximately 6 months). | The Impact monitor mouthguard measures rotation of the head. |
| Impact Monitor Mouthguard Head Impacts | Beginning of practice to last game (approximately 6 months). | The Impact monitor mouthguard measures the number of head impacts. |
Countries
United States
Contacts
PRINCIPAL_INVESTIGATORMario Hevesi, MD, PhD
Mayo Clinic
Outcome results
None listed